Hanger — Investor Presentation (December 2018)
30 slides from Hanger's investor presentation, Dec 4, 2018
Slide 1: Cautionary Note Forward Looking Statements
Cautionary Note Forward Looking Statements page 02 This presentation contains certain “forward-looking statements” relating to the Company. All statements, other than statements of historical fact included herein, are “forward looking statements.” These forward looking statements are often identifie
Slide 2: Hanger At a Glance
Hanger At a Glance page 03 Who We Are: Industry leader in orthotics and prosthetics (O&P) services $4.1 billion1 addressable O&P domestic U.S. market Pioneered prosthetic devices in 1861 Focus on custom devices By The Numbers (2017): Net Revenue $1.041 billion Adjusted EBITDA2 $120 million 4,600 emp
Slide 3: Business Mix: Primary Focus on the Provision of Specialty Health Care
Business Mix Primary Focus on the Provision of Specialty Health Care page 04 Patient Care $852.0 million 81.9% revenue Patient Care $148.0 million 17.4% margin G&A expense ($66.9) million Products & Services $188.8 million 18.1% revenue Products & Services $38.5 million 20.4% margin 2017 Hanger Net
Slide 4: Investment Thesis: Industry Leader With Multiple Strategic Advantages
Investment Thesis Industry Leader With Multiple Strategic Advantages page 05 The leading provider of orthotic and prosthetic services in the United States 1 $4.1 billion market for prescription prostheses, orthoses and prefabricated/off-the-shelf orthoses, and related services. Demand drivers are br
Slide 5: Agenda: Discussion Points
page 06 Our Market Focused Growth Strategy Patient Care Financial Performance Discussion Points Agenda Products & Services
Slide 6: Agenda: Discussion Points
page 07 Our Market Focused Growth Strategy Patient Care Financial Performance Discussion Points Agenda Products & Services
Slide 7: Orthotics and Prosthetics (O&P)
Orthotics and Prosthetics (O&P) Over 90% of Hanger’s revenue is related to O&P page 08 Prosthetic devices replace a missing limb or portion of a limb Provided to patients with amputated or congenitally absent limbs to replace the function and appearance of a limb Prosthetics are customized to meet t
Slide 8: Agenda: Discussion Points
page 09 Our Market Focused Growth Strategy Patient Care Financial Performance Discussion Points Agenda Products & Services
Slide 9: Patient Care Differentiators
Patient Care Differentiators Building Sustainable Advantages in a Fragmented Industry page 010 National network and market leadership Enhancing productivity and cost management through an enterprise supply chain Driving patient engagement, connectivity and satisfaction Optimizing reimbursement throu
Slide 10: Scale as a Competitive Advantage
Scale as a Competitive Advantage National Network Brings Hanger Closer to the Community page 011 1 1,500 Clinicians Hanger employs over 20% of the board certified, O&P clinicians in the U.S. Competitors are spread out in small local practitioner settings. 3 800 Patient Care Locations Hanger is the o
Slide 11: Market Leader In a Fragmented Industry
page 012 Market Leader In a Fragmented Industry O&P Patient Care Clinic Market (by location) Approximately 3,400 Clinics Hanger Clinic 15 next largest O&P providers ranging from 14 - 26 clinics Veterans Administration Rest of market 20% of O&P clinics in the nation Hanger currently operates 786 pati
Slide 12: Agenda: Discussion Points
page 013 Our Market Focused Growth Strategy Patient Care Financial Performance Discussion Points Agenda Products & Services
Slide 13: Products and Services: National Scale Supports Profitable Growth
Products and Services National Scale Supports Profitable Growth page 014 68% of products & services net revenue derived from the distribution of O&P components and related devices through “SPS” Provides comprehensive catalog to independent O&P providers nationwide A one-stop destination O&P industry
Slide 14: Agenda: Discussion Points
page 015 Our Market Focused Growth Strategy Patient Care Financial Performance Discussion Points Agenda Products & Services
Slide 15: Growth Strategy: Build a Durable and Scalable Platform
Growth Strategy Build a Durable and Scalable Platform page 016 Accomplishments: Stabilize and Invest G&A investment – leadership, infrastructure, technology Complete restatement of financials (May 2017) Listed on NYSE (September 2018) Operational initiatives Centralized revenue cycle management (RCM
Slide 16: Growth Strategy: Accelerate to Growth
page 017 Drive organic revenue growth via market share Drive to exceed industry growth rate of 1.5 - 2.0% Add clinicians Drive higher throughput and productivity Higher volume through referrals Focus on high-value customized devices Growth Strategy Accelerate to Growth 2019 - 2020 2020-Beyond 2015 -
Slide 17: Agenda: Discussion Points
page 018 Our Market Focused Growth Strategy Patient Care Financial Performance Discussion Points Agenda Products & Services
Slide 18: Historical Performance: Annual and Recent Quarter Net Revenue
Historical Performance Annual and Recent Quarter Net Revenue page 019 Implemented claims documentation initiatives in 2016 to improve long-term revenue quality Revenue growth in both business segments in the second and third quarters of 2018 Third Quarter $258.0 $262.9 2017 2018 $1,012.1 $1,067.2 $1
Slide 19: Historical Performance: Annual and Recent Quarter Adjusted EBITDA
Historical Performance Annual and Recent Quarter Adjusted EBITDA1 page 020 2017 Adjusted EBITDA improvement resulted primarily from lower disallowed revenue, personnel expenses and operating expenses in the Patient Care segment Products and Services segment declined on lower revenue from therapeutic
Slide 20: Transformation Yields Results: Same Clinic Revenue Per Day
Transformation Yields Results Annual and Quarterly Same Clinic Revenue Per Day page 021 Annual % change1 Revenue impacted by claims documentation initiative Quarterly % change1 Since its re-engineering of processes in 2016, Hanger has re-established consistent same clinic growth Q3 2018 same clinic
Slide 21: Payor Mix and Accounts Receivables Trend
page 022 Payor Mix and Accounts Receivables Trend Multi-Year Improvements in Working Capital Conversion Accounts Receivable, net (Orange Bars) $ thousands Day Sales Outstanding (Black Line) Diverse reimbursement mix combined with improved A/R aging has driven stronger working capital characteristics
Slide 22: Leverage: Favorable Deleveraging Trend
page 023 Leverage Favorable Deleveraging Trend Indebtedness Leverage Ratio As of September 30, 2018 3.4 3.6 3.8 4.0 4.2 4.4 4.6 $425.0 $450.0 $475.0 $500.0 $525.0 2014 2015 2016 2017 2018 Q3 Net Debt Leverage Ratio 2018 1 Revolver - $ Term B Loan, Due 2024 (L+350) 502.5 Seller Notes 3.8 Financial Le
Slide 23: Other Considerations: Use Excess Cash Flow to Execute Growth Strategy
Other Considerations Use Excess Cash Flow to Execute Growth Strategy page 024 $344.2 million, or 66%, of debt hedged or otherwise bearing fixed rate Current rate of approximately $33 million in annualized cash interest expense, or 6.3% Flexible Balance Sheet2 Q3 2018 TTM Free Cash Flow (Adjusted EBI
Slide 24: 2018 Outlook Generally Consistent with 2017
2018 Outlook Generally Consistent with 2017 page 025 For the full year 2018, Hanger anticipates net revenue and Adjusted EBITDA to be generally consistent with actual 2017 results Net Income and Adjusted Net Earnings1 Hanger anticipates net income and adjusted net earnings on a total and per share b
Slide 25: Investment Thesis: Industry Leader With Multiple Strategic Advantages
Investment Thesis Industry Leader With Multiple Strategic Advantages page 026 The leading provider of orthotic and prosthetic services in the United States 1 $4.1 billion market for prescription prostheses, orthoses and prefabricated/off-the-shelf orthoses, and related services. Demand drivers are b
Slide 26: Appendix: Non-GAAP Reconciliations
Appendix Non-GAAP Reconciliations
Slide 27: Non-GAAP Reconciliations: Net Income to Segment Adjusted EBITDA
Non-GAAP Reconciliations Net Income to Segment, Adjusted EBITDA and Adjusted EBITDA Margin as a Percentage of Net Revenue 2017 page 029 For the Year Ended December 31, 2017 Patient Care Net income (loss) - as reported (GAAP) 90,350 Adjustments to calculate EBITDA: Depreciation and amortization 21,36
Slide 28: Non-GAAP Reconciliations: Net Income to Adjusted EBITDA Third Quarter and YTD
Non-GAAP Reconciliations Net Income to Adjusted EBITDA Third Quarter and YTD 2018 v. 2017 page 030
Slide 29: Non-GAAP Reconciliations: Net Income to Adjusted EBITDA TTM September 30, 2018
Non-GAAP Reconciliations Net Income to Adjusted EBITDA TTM September 30, 2018 page 031 For the Trailing Twelve Months Ended September 30, 2018 Net income (loss) - as reported (GAAP) (89,734) $ Adjustments to calculate EBITDA: Depreciation and amortization 37,217 Interest expense, net 43,008 Loss on
Slide 30: Non-GAAP Reconciliations
Non-GAAP Reconciliations Net Income to Adjusted EBITDA TTM September 30, 2018 For the Trailing Twelve Months Ended September 30, 2018 Net income (loss) - as reported (GAAP) $ (89,734) Adjustments to calculate EBITDA: Depreciation and amortization 37,217 Interest expense, net 43,008 Loss on extinguis